ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
Executive Summary
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
You may also be interested in...
Will Intercept Drop OCA For NASH Following Negative FDA Panel Review?
Company tells advisory committee it is unsure of continuing on to collect Phase III outcomes data in NASH without accelerated approval, which the panel voted against.
Viking’s Phase IIb NASH Data Provide Across-The-Board Success
Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.
ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA
The cost-effectiveness group voted by a slight margin that Madrigal’s non-alcoholic steatohepatitis drug offers benefit above lifestyle changes alone, but decisively that Intercept’s candidate does not.